Author of

• 20152

  +

  P1.03 - Chemotherapy/Targeted Therapy (ID 689)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Chemotherapy/Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22592

    +

    P1.03-037 - A Phase II Study of Adjuvant Chemotherapy with Docetaxel plus Nedaplatin for Completely Resected Non-Small Cell Lung Cancer (ID 9631)

    09:30 - 09:30  |  Author(s): T. Hori
    • Abstract

    Background:
    Nedaplatin, a cisplatin derivative, has similar activity to cisplatin for non-small-cell lung cancer (NSCLC). We previous reported that the combination chemotherapy of docetaxel plus nedaplatin was well tolerated in patients with advanced NSCLC. The purpose of this phase II study was to evaluate the feasibility of combination chemotherapy of docetaxel plus nedaplatin as an adjuvant chemotherapy in patients with completely resected stage IB-IIIA NSCLC.
    
    Method:
    Following a radical surgery, patients were treated with docetaxel (60 mg/m[2]) and nedaplatin (80 mg/m[2]) on day 1 every four weeks up to four cycles. The primary endpoint was feasibility, determined by the proportion of patients who completed four cycles of the combination chemotherapy. Adverse events were graded according to National Cancer Institute Common Toxicity Criteria (version 4.0). Median relapse-free survival time after surgery was calculated by analyzed by Kaplan-Meier analysis.
    
    Result:
    From December 2010 and April 2016, 34 patients with median age of 64.5 years (range, 36–77 years) were enrolled in this study. The patients consisted of 30 males and four females. Histological types were adenocarcinomas in 20 patients, squamous cell carcinomas in 12, and others in 2. Pathological stages were IB in 2 patients, II in 21, and IIIA in 11. Concerning the feasibility of the combination adjuvant chemotherapy, twenty-six patients (76.5%) completed four cycles of the combination chemotherapy. In 11 of those patients (42.3%), doses of the agents were decreased from the initial doses due to toxicities. Grade 3 or 4 toxicities included leukopenia (36.4%), neutropenia (69.5), anemia (1.7%), thrombocytopenia (0.8%), anorexia (7.6%), and nausea (3.4%). There were no treatment-related deaths. Median relapse-free survival time after the surgery was not reached, and 5-year survival rate was 65.8%.
    
    Conclusion:
    Given high completion rate of adjuvant chemotherapy with docetaxel plus nedaplatin, we conclude that the adjuvant chemotherapy is feasible and tolerable in patients with completely resected NSCLC.